Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis

Conditions

• Moderate Plaque Psoriasis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Guselkumab — DRUG
  Guselkumab will be administered as subcutaneous injection.
• Placebo — DRUG
  Placebo will be administered as subcutaneous injection.

Study Details

The purpose of this study is to evaluate the efficacy of guselkumab compared to an inactive drug in participants with low body surface area moderate plaque psoriasis and special site involvement.

Key Dates

Start date

Aug 24, 2023

Status verified

Apr 2026

Primary completion

Apr 14, 2025

Completion

Apr 14, 2025

Study Design

Enrollment

338 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Group 1: Guselkumab
  Participants will receive guselkumab by subcutaneous injection with placebo as needed to maintain the blind.
• Placebo Comparator: Group 2: Placebo
  Participants will receive placebo by subcutaneous injection then receive guselkumab by subcutaneous injection.

Primary Outcome Measure

Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16 [ Time Frame: Week 16 ]

Locations (45)

Related coverage on Hipa.ai

• Guselkumab Phase 3 Trial Shows Efficacy in Moderate Plaque Psoriasis
  Guselkumab · May 1, 2026 · ClinicalTrials.gov
• Guselkumab Phase 3 for Moderate Plaque Psoriasis Hits Key Efficacy Endpoints
  Guselkumab · Apr 14, 2025 · ClinicalTrials.gov

Find similar trials in Birmingham, AL